The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after Stroke

Other authors

Institut Català de la Salut

[Ulm L] NeuroCure Clinical Research Center, Charité – Universitaetsmedizin Berlin, Berlin, Germany. Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia. Department of Neurology and Center for Stroke Research Berlin, Charité – Universitaetsmedizin Berlin, Berlin, Germany. [Hoffmann S] NeuroCure Clinical Research Center, Charité – Universitaetsmedizin Berlin, Berlin, Germany. Department of Neurology and Center for Stroke Research Berlin, Charité – Universitaetsmedizin Berlin, Berlin, Germany. [Nabavi D, Hermans M] Department of Neurology, Vivantes Klinikum Neukoelln, Berlin, Germany. [Mackert BM, Hamilton F] Department of Neurology, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany. [Montaner J, Bustamante A] Grup Malalties neurovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2021-04-29T11:19:27Z

2021-04-29T11:19:27Z

2017-04-24



Abstract

Profilaxi antibiòtica; Infeccions; Pneumònia


Profilaxis antibiótica; Infecciones; Neumonía


Antibiotic prophylaxis; Infections; Pneumonia


Background: Pneumonia is among the most common acute complications after stroke and is associated with poor long-term outcome. Biomarkers may help identifying stroke patients at high risk for developing stroke-associated pneumonia (SAP) and to guide early treatment. Aims: This trial investigated whether procalcitonin (PCT) ultrasensitive (PCTus)-guided antibiotic treatment of SAP can improve functional outcome after stroke. Methods: In this international, multicenter, randomized, controlled clinical trial with blinded assessment of outcomes, patients with severe ischemic stroke in the middle cerebral artery territory were randomly assigned within 40 h after symptom onset to PCTus-based antibiotic therapy guidance in addition to stroke unit care or standard stroke unit care alone. The primary endpoint was functional outcome at 3 months, defined according to the modified Rankin Scale (mRS) and dichotomized as acceptable (≤4) or unacceptable (≥5). Secondary endpoints included usage of antibiotics, infection rates, days of fever, and mortality. The trial was registered with http://ClinicalTrials.gov (Identifier NCT01264549). Results: In the intention-to-treat-analysis based on 227 patients (112 in PCT and 115 in control group), 197 patients completed the 3-month follow-up. Adherence to PCT guidance was 65%. PCT-guided therapy did not improve functional outcome as measured by mRS (odds ratio 0.79; 95% confidence interval 0.45–1.35, p = 0.47). Pneumonia rate and mortality were similar in both groups. Days with fever tended to be lower (p = 0.055), whereas total number of days treated with antibiotics were higher (p = 0.004) in PCT compared to control group. A post hoc analysis including all PCT values in the intention-to-treat population demonstrated a significant increase on the first day of infection in patients with pneumonia and sepsis compared to patients with urinary tract infections or without infections (p < 0.0001). Conclusion: PCTus-guided antibiotic therapy did not improve functional outcome at 3 months after severe ischemic stroke. PCT is a promising biomarker for early detection of pneumonia and sepsis in acute stroke patients.


This trial was supported by the European Union (FP7/2008-2013; 201024 and 202213), the German Ministry for Health and Education (01EO0801), the German Research Foundation (Exc257, SFB-TRR84, UL423/1-1), and Thermo Fisher Scientific BRAHMS GmbH, Germany.

Document Type

Article


Published version

Language

English

Publisher

Frontiers Media

Related items

Frontiers in Neurology;8

http://journal.frontiersin.org/article/10.3389/fneur.2017.00153/full

info:eu-repo/grantAgreement/EC/FP7/201024

info:eu-repo/grantAgreement/EC/FP7/202213

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)